Gossamer Bio, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $48.5M | $114.7M | $0 | $0 | — |
| Research and development | $174.1M | $138.5M | $135.3M | $170.9M | $170.3M |
| Operating expenses | $219.2M | $174.6M | $183.8M | $218.6M | $216.1M |
| Operating income | -$170.7M | -$59.9M | -$183.8M | -$218.6M | -$216.1M |
| Interest expense | $11.0M | $11.5M | $13.5M | $13.9M | $19.4M |
| Pretax income | -$170.5M | -$55.6M | -$179.8M | -$229.4M | -$234.0M |
| Income tax expense | -$88,000 | $893,000 | $0 | $0 | — |
| Net income | -$170.4M | -$56.5M | -$179.8M | -$229.4M | -$234.0M |
| Balance Sheet | |||||
| Cash and equivalents | $37.7M | $46.1M | $32.1M | $112.0M | $183.4M |
| Current assets | $167.6M | $309.9M | $306.5M | $261.9M | $331.8M |
| Total assets | $172.2M | $315.3M | $311.9M | $272.4M | $343.7M |
| Current liabilities | $63.4M | $45.0M | $51.6M | $49.2M | $39.9M |
| Total liabilities | $295.0M | $285.8M | $249.1M | $260.4M | $222.2M |
| Stockholders' equity | -$122.8M | $29.5M | $62.8M | $12.1M | $121.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$171.3M | -$3.5M | -$159.2M | -$187.0M | -$188.9M |
| Depreciation and amortization | $24,000 | $833,000 | $1.6M | $1.8M | $1.7M |
| Stock-based compensation | $10.6M | $20.6M | $28.5M | $42.6M | $32.0M |
| Capital expenditure | $79,000 | $0 | $0 | $410,000 | $1.5M |
| Free cash flow | -$171.3M | -$3.5M | -$159.2M | -$187.4M | -$190.4M |
Shares outstanding 234.7M · Free float 81.9%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.